Loading... Please wait...

Our Newsletter


GDC-0980 (RG7422) | PI3K/mTOR inhibitor

  • GDC-0980 (RG7422).jpg
  • GDC-0980 (RG7422), 400x400px, png
Price:
$149.00
Catalog #:
C4098-5
Quantity:


Product Description

GDC0980, a orally-available, thienopyrimidine-based, ATP-competitive dual inhibitor of PI3K class I isoforms (IC50 of 5, 27, 7, and 14 nM for PI3Ka, b, d, and g) and mTOR (Ki of 17 nM). [1] GDC0980 potently inhibits signal transduction (Thr308, Ser473) downstream of both PI3K and mTOR and showed most potent antitumor activity in breast, prostate, and lung cancer (IC50


Technical information:

Chemical Formula:   C23H30N8O3S
CAS #:   1032754-93-0
Molecular Weight:   498.6
Purity: > 98%
Appearance:   White
Chemical Name:   (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one
Solubility:   Up to 40 mM in DMSO
Synonyms:   GDC-0980, GDC0980, RG7422,

Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage condition: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.


Reference:

1. Sutherlin et al., Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer. J. Med. Chem. 2011, 54, 7579-7587. Pubmed ID: 21981714
2. Wallin et al., GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway, Mol. Cancer Ther. 2011, 10, 2426-2436. Pubmed ID: 21998291

Other Information:

Product Specification (pdf)
MSDS (pdf)
Certificate of Analysis is available upon request.

Find Similar Products by Category

Write your own product review

Product Reviews

This product hasn't received any reviews yet. Be the first to review this product!

Add to Wish List

Click the button below to add the GDC-0980 (RG7422) | PI3K/mTOR inhibitor to your wish list.

You Recently Viewed...